Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
Sponsor: Novartis Pharmaceuticals
Summary
This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan in subjects with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis
Official title: An Open-label, Non-randomized Extension Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Iptacopan (LNP023) in C3 Glomerulopathy or Idiopathic Immune-complex-membranoproliferative Glomerulonephritis
Key Details
Gender
All
Age Range
12 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
225
Start Date
2019-10-03
Completion Date
2036-05-30
Last Updated
2026-02-23
Healthy Volunteers
No
Interventions
LNP023
LNP023 capsules
Locations (49)
Childrens Hospital Colorado
Aurora, Colorado, United States
Georgia Nephrology Research Inst
Lawrenceville, Georgia, United States
University of Iowa Health Care
Iowa City, Iowa, United States
University of Minnesota
Minneapolis, Minnesota, United States
Col Uni Med Center New York Presby
New York, New York, United States
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Belo Horizonte, Minas Gerais, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
Botucatu, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Salvador, Brazil
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Erlangen, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Mainz, Germany
Novartis Investigative Site
Heraklion Crete., Greece
Novartis Investigative Site
Thessaloniki, Greece
Novartis Investigative Site
Petah Tikva, Israel
Novartis Investigative Site
Petah Tikva, Israel
Novartis Investigative Site
Ranica, BG, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Nagoya, Aichi-ken, Japan
Novartis Investigative Site
Asahikawa, Hokkaido, Japan
Novartis Investigative Site
Sapporo, Hokkaido, Japan
Novartis Investigative Site
Takatsuki, Osaka, Japan
Novartis Investigative Site
Ohtsu, Shiga, Japan
Novartis Investigative Site
Hachiōji, Tokyo, Japan
Novartis Investigative Site
Niigata, Japan
Novartis Investigative Site
Leiden, South Holland, Netherlands
Novartis Investigative Site
Pamplona, Navarre, Spain
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Seville, Spain
Novartis Investigative Site
Bern, Switzerland
Novartis Investigative Site
Köseköy, Kocaeli, Turkey (Türkiye)
Novartis Investigative Site
Kayseri, Melikgazi, Turkey (Türkiye)
Novartis Investigative Site
Ankara, Yenimahalle, Turkey (Türkiye)
Novartis Investigative Site
Newcastle upon Tyne, Tyne and Wear, United Kingdom
Novartis Investigative Site
Cardiff, United Kingdom
Novartis Investigative Site
London, United Kingdom